What is the current stock price of Marker Therapeutics, Inc. (MRKR)?

As of the latest market data, Marker Therapeutics, Inc. (MRKR) is trading at $1.75. The stock has seen a loss of 0.00% today.

Does Marker Therapeutics, Inc. (MRKR) pay a dividend?

Based on current data, Marker Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Marker Therapeutics, Inc.?

The current market capitalization of Marker Therapeutics, Inc. (MRKR) is approximately unavailable.

MRKR

Marker Therapeutics, Inc.·Healthcare

1.75

0.000%(+0.00)

Market Closed

1.80

2.857%(+0.05)

After Hours

Last Updated: — ET

52W L: $0.8152W H: $4.07

MRKR NEWS

zacks.com

Mar 18

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.

globenewswire.com

Mar 18

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

globenewswire.com

Feb 18

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 – 8:30 a.m.

zacks.com

Jan 21

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2002-07-16

Beta

1.47

Websitewww.markertherapeutics.com↗